Four genes predict the survival of osteosarcoma patients based on TARGET database

Li, Yuan; Ge, Fengxiao; Shuai-hua, Wang

doi:10.1007/s10863-020-09836-6

Cited by 9 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osteosarcoma is the most common primary bone tumour, and the five-year survival rate of patients with metastasis is much lower than that of patients without metastasis [ 19 ]. Yuan Li et al [ 20 ] demonstrated that the expression of four genes, HIPK2, MAP3K5, CK5, and KRT5, was correlated with survival risk by using a multivariate Cox proportional hazards model. These results show that KRT5, HIPK2, MAP3K5, and CD5 serve as prognostic factors in osteosarcoma patients.…”

Section: Discussionmentioning

confidence: 99%

A five metastasis-related long noncoding RNA risk signature for osteosarcoma survival prediction

Shao

Liu

et al. 2021

BMC Med Genomics

View full text Add to dashboard Cite

Background Osteosarcoma is a highly malignant and common bone tumour with an aggressive disease course and a poor prognosis. Previous studies have demonstrated the relationship between long noncoding RNAs (lncRNAs) and tumorigenesis, metastasis, and progression. Methods We utilized a large cohort from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database osteosarcoma project to identify potential lncRNAs related to the overall survival of patients with osteosarcoma by using univariate and multivariate Cox proportional hazards regression analyses. Kaplan–Meier curves were generated to evaluate the overall survival difference between patients in the high-risk group and the low-risk group. A time-dependent receiver operating characteristic curve (ROC) was employed, and the area under the curve (AUC) of ROC was measured to assess the sensitivity and specificity of the multi-lncRNA signature. Results Five lncRNAs (RP11-128N14.5, RP11-231|13.2, RP5-894D12.4, LAMA5-AS1, RP11-346L1.2) were identified, and a five-lncRNA signature was constructed. The AUC for predicting 5-year survival was 0.745, which suggested good performance of the five-lncRNA signature. In addition, functional enrichment analysis of the five-lncRNA-correlated protein-coding genes (PCGs) was performed to show the biological function of the five lncRNAs. Additionally, PPI network suggested RTP1 is a potential biomarker that regulates the prognosis of osteosarcoma. Conclusions We developed a five-lncRNA signature as a potential prognostic indicator for osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

A five metastasis-related long noncoding RNA risk signature for osteosarcoma survival prediction

Shao

Liu

et al. 2021

BMC Med Genomics

View full text Add to dashboard Cite

show abstract

“…Similarly, we observed upregulated expression of CDH1 and KRT5 (keratin 5), although the difference was not significant between monoculture and coculture. A recent bioinformatic study linked four key genes ( KRT5 , HIPK2 , MAP3K5 , and CD5 ) to osteosarcoma patient survival, with KRT5 expression positively correlated with survival risk . Other cell adhesion markers ( PECAM1 , CDH5 , and MCAM ) showed no clear changes upon coculture with PCa cells (Figure C).…”

Section: Resultsmentioning

confidence: 95%

“…A recent bioinformatic study linked four key genes (KRT5, HIPK2, MAP3K5, and CD5) to osteosarcoma patient survival, with KRT5 expression positively correlated with survival risk. 64 Other cell adhesion markers (PECAM1, CDH5, and MCAM) showed no clear changes upon coculture with PCa cells (Figure 4C). Comparing bone cells (Figure 4C) to PCa cells (Figure 2C), we observed different sets of cell adhesion markers being differentially regulated, indicating cell-specific responses.…”

Section: Cell Morphologies and Gene Expression Of Bone Cells In S-pic...mentioning

confidence: 97%

TempEasy 3D Hydrogel Coculture System Provides Mechanistic Insights into Prostate Cancer Bone Metastasis

Zhang,

Chen,

Sun

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Patients diagnosed with advanced prostate cancer (PCa) often experience incurable bone metastases; however, a lack of relevant experimental models has hampered the study of disease mechanisms and the development of therapeutic strategies. In this study, we employed the recently established Temperature-based Easy-separable (TempEasy) 3D cell coculture system to investigate PCa bone metastasis. Through coculturing PCa and bone cells for 7 days, our results showed a reduction in PCa cell proliferation, an increase in neovascularization, and an enhanced metastasis potential when cocultured with bone cells. Additionally, we observed increased cell proliferation, higher stemness, and decreased bone matrix protein expression in bone cells when cocultured with PCa cells. Furthermore, we demonstrated that the stiffness of the extracellular matrix had a negligible impact on molecular responses in both primary (PCa cells) and distant malignant (bone cells) sites. The TempEasy 3D hydrogel coculture system is an easy-to-use and versatile coculture system that provides valuable insights into the mechanisms of cell–cell communication and interaction in cancer metastasis.

show abstract

“…Common genetic alterations include mutations in tumor suppressor genes such as TP53 and RB1 and other involved alterations in pathways related to cell cycle regulation, apoptosis, and DNA repair mechanisms [9]. Extensive research has shown that many aberrant gene expression profiles are intimately connected to the hallmarks of osteosarcoma [10,11]. The comprehensive analysis of aberrant gene expression has important clinical significance for the early diagnosis, therapeutic management, recurrence risk, and prognosis prediction of osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Analysis Reveals Prognostic and Therapeutic Immunity-Related Biomarkers for Pediatric Metastatic Osteosarcoma

Yuan,

2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Osteosarcoma, the most prevalent malignant bone tumor in children and adolescents, presents a complex pathogenesis characterized by various genetic and epigenetic alterations. This study aims to identify key differentially expressed genes (DEGs) in pediatric osteosarcoma, with a focus on those influencing metastasis and patient survival. Materials and Methods: We utilized the GSE33382 dataset from the GEO database for a comprehensive bioinformatic analysis. This included a protein–protein interaction (PPI) network analysis, Cox regression, and Kaplan–Meier survival analysis to identify central DEGs associated with osteosarcoma metastasis and patient survival. Results: Our analysis identified 88 DEGs related to osteosarcoma metastasis. Among them, three survival-related central DEGs—C1QA, CD74, and HLA-DMA—were significantly linked to patient outcomes. Further correlation analysis established a strong relationship between these genes, tumor mutation burden (TMB), immune checkpoint gene expression, and overall survival. Notably, C1QA and CD74 exhibited higher expression in non-metastatic osteosarcoma cases, suggesting a potential role in disease progression. Conclusions: The identified DEGs, particularly C1QA, CD74, and HLA-DMA, may serve as critical biomarkers for pediatric osteosarcoma prognosis and potential targets for immunotherapy. These findings provide a deeper understanding of the molecular landscape of osteosarcoma and open new avenues for therapeutic intervention.

show abstract

Four genes predict the survival of osteosarcoma patients based on TARGET database

Cited by 9 publications

References 32 publications

A five metastasis-related long noncoding RNA risk signature for osteosarcoma survival prediction

A five metastasis-related long noncoding RNA risk signature for osteosarcoma survival prediction

TempEasy 3D Hydrogel Coculture System Provides Mechanistic Insights into Prostate Cancer Bone Metastasis

Comprehensive Analysis Reveals Prognostic and Therapeutic Immunity-Related Biomarkers for Pediatric Metastatic Osteosarcoma

Contact Info

Product

Resources

About